Krishna Vaddi

CIK: 0001824633

Transaction Breakdown

Open Market Buys (P)11 (84.6%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (15.4%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

PRLD

Prelude Therapeutics Inc

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (13 total)

PRLD
Prelude Therapeutics Inc
Feb 4, 2026
Award(A)
Employee Stock Option (right to buy)
Direct
837K shares-
PRLD
Prelude Therapeutics Inc
Mar 25, 2025
Purchase(P)
Direct
675K shares at avg. $0.69$467K
PRLD
Prelude Therapeutics Inc
Mar 21, 2025
Purchase(P)
Direct
15K shares at avg. $0.73$11K
PRLD
Prelude Therapeutics Inc
Mar 20, 2025
Purchase(P)
Direct
5.4K shares at avg. $0.73$4K
PRLD
Prelude Therapeutics Inc
Mar 17, 2025
Purchase(P)
Direct
9.1K shares at avg. $0.75$7K
PRLD
Prelude Therapeutics Inc
Mar 14, 2025
Purchase(P)
Direct
30K shares at avg. $0.75$23K
PRLD
Prelude Therapeutics Inc
Mar 13, 2025
Purchase(P)
Direct
50K shares at avg. $0.72$36K
PRLD
Prelude Therapeutics Inc
Mar 12, 2025
Purchase(P)
Direct
47.5K shares at avg. $0.71$34K
PRLD
Prelude Therapeutics Inc
Feb 4, 2025
Award(A)
Employee Stock Option (right to buy)
Direct
496K shares-
PRLD
Prelude Therapeutics Inc
Dec 31, 2024
Purchase(P)
Indirect
5K shares at avg. $1.21$6K
PRLD
Prelude Therapeutics Inc
Dec 30, 2024
Purchase(P)
Indirect
10K shares at avg. $1.20$12K
PRLD
Prelude Therapeutics Inc
Dec 19, 2024
Purchase(P)
Indirect
6.9K shares at avg. $0.89$6K
PRLD
Prelude Therapeutics Inc
Dec 18, 2024
Purchase(P)
Direct
100K shares at avg. $0.93$93K

		Type	Shares	Price		Ownership
Feb 4, 2026	PRLD Prelude Therapeutics Inc	Award(A) Employee Stock Option (right to buy)	837,000	-	-	Direct
Mar 25, 2025	PRLD Prelude Therapeutics Inc	Purchase(P)	675,000	$0.69	$467,438	Direct
Mar 21, 2025	PRLD Prelude Therapeutics Inc	Purchase(P)	15,000	$0.73	$10,959	Direct
Mar 20, 2025	PRLD Prelude Therapeutics Inc	Purchase(P)	5,416	$0.73	$3,950	Direct
Mar 17, 2025	PRLD Prelude Therapeutics Inc	Purchase(P)	9,106	$0.75	$6,829	Direct
Mar 14, 2025	PRLD Prelude Therapeutics Inc	Purchase(P)	29,999	$0.75	$22,631	Direct
Mar 13, 2025	PRLD Prelude Therapeutics Inc	Purchase(P)	50,000	$0.72	$35,820	Direct
Mar 12, 2025	PRLD Prelude Therapeutics Inc	Purchase(P)	47,500	$0.71	$33,744	Direct
Feb 4, 2025	PRLD Prelude Therapeutics Inc	Award(A) Employee Stock Option (right to buy)	496,000	-	-	Direct
Dec 31, 2024	PRLD Prelude Therapeutics Inc	Purchase(P)	5,000	$1.21	$6,044	Indirect
Dec 30, 2024	PRLD Prelude Therapeutics Inc	Purchase(P)	10,000	$1.20	$12,000	Indirect
Dec 19, 2024	PRLD Prelude Therapeutics Inc	Purchase(P)	6,888	$0.89	$6,116	Indirect
Dec 18, 2024	PRLD Prelude Therapeutics Inc	Purchase(P)	100,000	$0.93	$93,210	Direct

1-13 of 13 transactions

About Vaddi Krishna

Vaddi Krishna (SEC CIK 0001824633) files insider reports with the SEC as CEO of Prelude Therapeutics Inc (PRLD).

Signal8 holds 9 ownership filings by Vaddi Krishna, all Form 4s, filed between Dec 20, 2024 and Feb 5, 2026. Those filings report 13 transactions, from Dec 18, 2024 to Feb 4, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Vaddi Krishna's filings is in WILMINGTON, DE.

Recent filings by Vaddi Krishna

Feb 4, 2026: Grant or award of PRLD derivative securities (Form 4, code A).
Mar 25, 2025: Open-market purchase of PRLD shares (Form 4, code P).
Mar 21, 2025: Open-market purchase of PRLD shares (Form 4, code P).
Mar 20, 2025: Open-market purchase of PRLD shares (Form 4, code P).
Mar 17, 2025: Open-market purchase of PRLD shares (Form 4, code P).

Other insiders filing for Prelude Therapeutics Inc (PRLD)

BAKER BROS. ADVISORS LP, Director
Dorton Katina, Director
Babler Martin, Director
Bonita David P, Director
Sandor Victor, Director
FRIEDMAN PAUL A, Director

How to read Form 4 transaction codes